论文部分内容阅读
目的:对比吸入型糖皮质激素联合辅舒良及顺尔宁与吸入型糖皮质激素联合辅舒良治疗哮喘合并中重度持续性过敏性鼻炎的临床疗效。方法:将2011年1月至2013年1月广州医科大学第一附属医院收治的55例哮喘合并中重度持续性过敏性鼻炎患者作为研究对象,对照组使用吸入型糖皮质激素联合辅舒良治疗(20例),治疗组使用吸入型糖皮质激素联合辅舒良及顺尔宁联合治疗(35例)。治疗前及治疗后3个月,检测患者肺功能并进行病情症状及体征记分,并比较临床疗效。结果:观察组和对照组治疗后3个月肺功能指标第1秒用力呼气量占预计值百分比(FEV1%)、最大呼气中期流速占预计值百分比(MMEF%)与治疗前比较,差异均有统计学意义(P<0.05)。观察组治疗后MMEF%与对照组比较,差异有统计学意义(P<0.05)。治疗后3个月,患者过敏性鼻炎的喷嚏、流涕次数、鼻堵、鼻痒等症状均明显好转,其中观察组总有效率高于对照组(P<0.05)。结论:吸入型糖皮质激素联合辅舒良及顺尔宁能更有效控制患者支气管哮喘及中重度持续性过敏性鼻炎的临床症状,并显著提高肺功能。
Objective: To compare the clinical efficacy of inhaled glucocorticoids combined with Fu-Shu-Liang, Shun-Er-Ning and inhaled glucocorticoid in combination with Fu-Shu-Liang in the treatment of asthma with moderate-to-severe persistent allergic rhinitis. Methods: From January 2011 to January 2013, 55 cases of patients with moderate and severe persistent allergic rhinitis admitted to the First Affiliated Hospital of Guangzhou Medical University were enrolled in this study. Patients in the control group were treated with inhaled corticosteroids plus Fu Shu Liang (N = 20). The treatment group was treated with inhaled glucocorticoids combined with Fu-Shu-Liang and Sulfonam (35 cases). Before treatment and 3 months after treatment, the lung function of patients was tested and the symptoms and signs of illness were scored, and the clinical efficacy was compared. Results: In the observation group and the control group, the FEV1%, FEV1%, and the maximum expiratory flow rate (%) of predicted value of pulmonary function parameters at 3 months after treatment were significantly different from those before treatment All were statistically significant (P <0.05). Compared with the control group, the MMEF% in the observation group after treatment was significantly different (P <0.05). At 3 months after treatment, the symptoms of allergic rhinitis such as sneezing, runny nose, nasal congestion and nasal itching were all significantly improved. The total effective rate in observation group was higher than that in control group (P <0.05). Conclusion: Inhaled glucocorticoid combined with Fu-Shu-Liang and Shun-Ning can more effectively control the clinical symptoms of patients with bronchial asthma and moderate-to-severe persistent allergic rhinitis and significantly improve pulmonary function.